“We are expanding our product capabilities as well as advancing solutions that are directly aligned with our professional market focus in oral health.” Marco Witteveen, CEO of Magnasense AB
October – December 2024*
• Total income, including other income and revenue, amounted to SEK 5.3M (2.9M)
• Loss before tax amounted to SEK -23.8M (-10.9M)
• Cash and cash equivalents at the end of the quarter was SEK 0.3M (12.1M)
• Loss per share** SEK -0.41 (-0.40)
• Equity ratio*** at 31 December 2024 was -119% (0%)
Hechos significativos del periodo
• Directed issue of 13,090,908 shares to Atlas Special Opportunities following conversions totalling SEK 3.0M.
• Magnasense AB completed the NIH RADx® Tech Project.
Hechos significativos posteriores al periodo
- The Company announced its intention to carry out a rights issue of approx. SEK 26M to continue to develop saliva-based diagnostics as an alternative to blood testing.
- An EGM granted the Board Members the authorisation to proceed with the rights issue.
- Termination of Agreement with Digital Health Solutions (”DHS”), LLC; as part of the termination, DHS agreed to waive 9,500,000 warrants.
- A directed issue of 22,420,632 shares to Atlas Special Opportunities LLC following conversions totalling SEK 2.50M.
- Magnasense Technologies Oy and Salofa Oy reached a settlement
* Compared to the same period in 2023
** Loss per share: Profit for the quarter divided by the weighted average number of shares for the quarter, which as of 2024-12-31 amounted to 57,216,914 shares before dilution. The corresponding number for the same period in the previous year was 26,474,698 shares.
*** Ratio de fondos propios: Fondos propios divididos por el activo total.
This information is information that Magnasense is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-05 08:00 CEST.
ES 
EN